Residency · Fairborn, OH
Sponsored by Wright State University Boonshoft School of Medicine
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.
The New England journal of medicine · 2025 · 63 citations · David Carr
Energy-based devices for the treatment of Acne Scars: 2022 International consensus recommendations.
Lasers in surgery and medicine · 2022 · 76 citations · Jill Waibel
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial.
Journal of the American Academy of Dermatology · 2026 · 13 citations · Rocco Serrao
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
Journal of the American Academy of Dermatology · 2021 · 116 citations · Jill Waibel
riSCC: A personalized risk model for the development of poor outcomes in cutaneous squamous cell carcinoma.
Journal of the American Academy of Dermatology · 2025 · 20 citations · David Carr
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial.
Pediatric dermatology · 2025 · 19 citations ·
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
Lancet (London, England) · 2025 · 22 citations · Jill Waibel
Impact of immunosuppression on cutaneous squamous cell carcinoma outcomes.
Journal of the American Academy of Dermatology · 2026 · 8 citations · David Carr